The cisplatin-resistant PDX model showed no response to cisplatin treatment, whereas MYCi975 alone or MYCi975 plus cisplatin significantly inhibited tumor growth in terms of volume and weight (Figure 4B, 4C and 4D), suggesting that MYC inhibition overcame cisplatin resistance of HNSCC in vivo. Here, MYC is linked to head and neck squamous cell carcinoma.